These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26453682)

  • 1. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Signoriello E; Lanzillo R; Brescia Morra V; Di Iorio G; Fratta M; Carotenuto A; Lus G
    Mult Scler; 2016 Jun; 22(7):921-5. PubMed ID: 26453682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.
    Kolcava J; Hulova M; Rihova L; Bednarik J; Stourac P
    Neurol Sci; 2021 Jul; 42(7):2847-2853. PubMed ID: 33201361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report.
    Văcăraş V; Major ZZ; Buzoianu AD
    Neurol Neurochir Pol; 2017; 51(3):221-226. PubMed ID: 28392137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
    Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
    Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL; Rotstein DL; Healy BC; Chitnis T; Weiner HL; Buckle GJ
    Mult Scler; 2014 Sep; 20(10):1381-90. PubMed ID: 24852928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
    Rossi S; Motta C; Studer V; Monteleone F; De Chiara V; Buttari F; Barbieri F; Bernardi G; Battistini L; Cutter G; Stüve O; Salvetti M; Centonze D
    Mult Scler; 2013 Jan; 19(1):59-68. PubMed ID: 22577119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness and safety of natalizumab in a Portuguese population.
    Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.